UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the month of March 2012

Commission File Number: 001-31368

 

 

SANOFI

(Translation of registrant’s name into English)

 

 

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  x            Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨             No  x

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-            

 

 

 

---

In March 2012, Sanofi issued the press releases attached hereto as Exhibits 99.1 to 99.3 which are incorporated herein by reference.

Exhibit List

 

Exhibit No.		Description
Exhibit 99.1		Press release dated March 16, 2012: Sanofi to Acquire Pluromed, Inc., Expanding its Presence in Biosurgery
Exhibit 99.2		Press release dated March 26, 2012: Sanofi and Regeneron Report Phase 2 Data for Potential First-in-Class Lipid-Lowering PCSK9 Antibody
Exhibit 99.3		Sales by geographic region for Genzyme key products in 2011
		From 2012, Sanofi financial press releases will include Genzyme sales, consisting of Rare Diseases products (Cerezyme®, Myozyme®/Lumizyme®, Fabrazyme® and Other Rare Diseases products) and Multiple Sclerosis products.   Sanofi will continue to provide sales of Renagel®/Renvela® and Synvisc®/Synvisc One® which are now part of Sanofi pharmaceuticals.

 

2

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: March 30, 2012						SANOFI
				By		/S/ John Felitti
				Name:		John Felitti
				Title:		Associate Vice President,
						Corporate Law, Financial & Securities Law

 

3

---

Exhibit Index

 

Exhibit No.		Description
Exhibit 99.1		Press release dated March 16, 2012: Sanofi to Acquire Pluromed, Inc., Expanding its Presence in Biosurgery
Exhibit 99.2		Press release dated March 26, 2012: Sanofi and Regeneron Report Phase 2 Data for Potential First-in-Class Lipid-Lowering PCSK9 Antibody
Exhibit 99.3		Sales by geographic region for Genzyme key products in 2011
		From 2012, Sanofi financial press releases will include Genzyme sales, consisting of Rare Diseases products (Cerezyme®, Myozyme®/Lumizyme®, Fabrazyme® and Other Rare Diseases products) and Multiple Sclerosis products.   Sanofi will continue to provide sales of Renagel®/Renvela® and Synvisc®/Synvisc One® which are now part of Sanofi pharmaceuticals.

 

4